Status:
COMPLETED
Immunogenicity and Safety of Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases
Lead Sponsor:
GlaxoSmithKline
Conditions:
Mumps
Rubella
Eligibility:
All Genders
11-21 years
Phase:
PHASE4
Brief Summary
This is a study to assess the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals live attenuated measles-mumps-rubella-varicella vaccine given to healthy children in their second year of l...
Eligibility Criteria
Inclusion
- A male or female subject between 11-13 months of age (i.e. from 11 month birthday until the day before the 14 month birthday) at the time of the first vaccination.
Exclusion
- History of previous measles, mumps, rubella and/or varicella vaccination or disease, or known exposure to any of these diseases within 30 days prior to the start of the trial
- Planned administration of a vaccine not foreseen by the study protocol from 30 days prior to each vaccination until 42-56 days after each vaccination
Key Trial Info
Start Date :
May 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2005
Estimated Enrollment :
1439 Patients enrolled
Trial Details
Trial ID
NCT00126997
Start Date
May 1 2005
End Date
November 1 2005
Last Update
September 21 2016
Active Locations (54)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Espoo, Finland, 02100
2
GSK Investigational Site
Lahti, Finland, 15140
3
GSK Investigational Site
Oulu, Finland, 90100
4
GSK Investigational Site
Pori, Finland, 28120